Dementia epidemiology.
暂无分享,去创建一个
[1] H. Gertz,et al. The prognosis of mild cognitive impairment in the elderly. , 1998, Journal of neural transmission. Supplementum.
[2] E. Perry,et al. Operational criteria for senile dementia of Lewy body type (SDLT) , 1992, Psychological Medicine.
[3] G. Rauch,et al. Cardiovascular and Other Risk Factors for Alzheimer's Disease and Vascular Dementia , 2000, Annals of the New York Academy of Sciences.
[4] C. Brayne,et al. Vascular Risks and Incident Dementia: Results from a Cohort Study of the Very Old , 1998, Dementia and Geriatric Cognitive Disorders.
[5] L. Nee,et al. Alzheimer’s Disease in 22 Twin Pairs – 13-Year Follow-Up: Hormonal, Infectious and Traumatic Factors , 1999, Dementia and Geriatric Cognitive Disorders.
[6] Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.
[7] I. Perry. Homocysteine and Risk of Stroke , 1999, Journal of cardiovascular risk.
[8] H. Steiner,et al. Genes and mechanisms involved in β-amyloid generation and Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[9] K. Marder,et al. Alzheimer's disease after remote head injury: an incidence study. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[10] B. Winblad,et al. Tau gene polymorphisms and apolipoprotein E ε4 may interact to increase risk for Alzheimer’s disease , 1999, Neuroscience Letters.
[11] L. Bouter,et al. Education and incident Alzheimer's disease: a biased association due to selective attrition and use of a two-step diagnostic procedure? , 1999, International journal of epidemiology.
[12] W. Meier-Ruge,et al. Mitochondrial Genome Lesions in the Pathogenesis of Sporadic Alzheimer’s Disease , 1999, Gerontology.
[13] J. Breitner. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal , 1996, Neurobiology of Aging.
[14] J. Haines,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.
[15] Steven M. Horvath,et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.
[16] S. Dimauro,et al. Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[17] B. Winblad,et al. Mild cognitive impairment--an early stage of Alzheimer's disease? , 1998, Journal of neural transmission. Supplementum.
[18] M. Bullido,et al. A polymorphism in the tau gene associated with risk for Alzheimer's disease , 2000, Neuroscience Letters.
[19] L. Beckett,et al. Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease , 1998, Alzheimer disease and associated disorders.
[20] K. Morgan,et al. Genetic risk factors in Alzheimer's disease. , 1998, Molecular pathology : MP.
[21] L. Pantoni,et al. Hachinski's ischemic score and the diagnosis of vascular dementia: A review , 1993, The Italian Journal of Neurological Sciences.
[22] J. Yesavage,et al. α2 Macroglobulin and the risk of Alzheimer’s disease , 2000, Neurology.
[23] A. Hoes,et al. NSAIDs and incident Alzheimer’s disease. the Rotterdam study , 1998, Neurobiology of Aging.
[24] C. Morris,et al. Lack of association of the α2-macroglobulin locus on chromosome 12 in AD , 2000, Neurology.
[25] P. Celsis,et al. Age-related cognitive decline, mild cognitive impairment or preclinical Alzheimer's disease? , 2000, Annals of medicine.
[26] C. Brayne. The EURODEM collaborative re-analysis of case-control studies of Alzheimer's disease: implications for public health. , 1991, International journal of epidemiology.
[27] B. Ghetti,et al. Mutations in the Tau gene cause frontotemporal dementia , 1999, Brain Research Bulletin.
[28] W. Jagust,et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. , 2000, Archives of neurology.
[29] G. C. Román,et al. Vascular dementia , 1993, Neurology.
[30] W F Stewart,et al. Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.
[31] J. Treanor,et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.
[32] W. Jagust,et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers , 1992, Neurology.
[33] Ove Almkvist,et al. Early diagnosis of Alzheimer dementia based on clinical and biological factors , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[34] R. Horwitz,et al. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. , 1997, Journal of clinical epidemiology.
[35] S. Sisodia. Alzheimer's disease: perspectives for the new millennium. , 1999, The Journal of clinical investigation.
[36] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[37] E. Kokmen,et al. Incidence of dementia and Alzheimer's disease: a reanalysis of data from Rochester, Minnesota, 1975-1984. , 1998, American journal of epidemiology.
[38] A D Roses,et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.
[39] M. Doran,et al. Undifferentiated dementia, Alzheimer's disease and vascular dementia: Age- and gender-related incidence in Liverpool , 1999, British Journal of Psychiatry.
[40] D. Carter,et al. Ibuprofen: effect on inducible nitric oxide synthase. , 1997, Brain research. Molecular brain research.
[41] G Gainotti,et al. Sensitivity and Specificity of Some Neuropsychological Markers of Alzheimer Dementia , 1998, Alzheimer disease and associated disorders.
[42] A. Sinclair,et al. Mitochondrial DNA mutations in Alzheimer's disease. , 1997, Biochemical and biophysical research communications.
[43] A. Hofman,et al. Estrogen use and early onset Alzheimer's disease: a population-based study , 1999, Journal of neurology, neurosurgery, and psychiatry.
[44] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[45] V. Hachinski,et al. Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. , 2000, Archives of neurology.
[46] R. Barbour,et al. Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.
[47] V. Hachinski. Multi-infarct dementia: a reappraisal. , 1991, Alzheimer disease and associated disorders.
[48] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[49] G. Román. A historical review of the concept of vascular dementia: lessons from the past for the future. , 1999, Alzheimer disease and associated disorders.
[50] T. Bird,et al. Recent Advances in the Genetics of Alzheimer's Disease , 1998, Journal of geriatric psychiatry and neurology.
[51] A. Roses,et al. Cognitive function and apolipoprotein E in very old adults: findings from the Nun Study. , 2000, The journals of gerontology. Series B, Psychological sciences and social sciences.
[52] C. Czech,et al. The Role of Presenilin-1 in the γ-Secretase Cleavage of the Amyloid Precursor Protein of Alzheimer's Disease* , 2000, The Journal of Biological Chemistry.
[53] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[54] L. Bouter,et al. Cognitive reserve and mortality in dementia: the role of cognition, functional ability and depression , 1999, Psychological Medicine.
[55] B. Shastry,et al. Genes and susceptible loci of Alzheimer’s disease , 1999, Brain Research Bulletin.
[56] D L Price,et al. Alzheimer's disease: genetic studies and transgenic models. , 1998, Annual review of genetics.
[57] D. Jolley,et al. Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia , 1989 .
[58] R Brookmeyer,et al. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.
[59] E G Tangalos,et al. Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.
[60] R. Brookmeyer,et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.
[61] A. Hofman,et al. Head trauma and risk of dementia and Alzheimer’s disease , 1999, Neurology.
[62] R. Tanzi,et al. REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease , 1996, Neurobiology of Disease.
[63] A. Hofman,et al. Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.
[64] David G. Tew,et al. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.
[65] M. Albert,et al. Genetic association of an (α2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease , 1998 .
[66] G. Schellenberg,et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. , 1997, American journal of epidemiology.
[67] K. Hall,et al. Low education and childhood rural residence , 2000, Neurology.
[68] Alfredo G. Tomasselli,et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.
[69] R Doll,et al. Smoking and dementia in male British doctors: prospective study , 2000, BMJ : British Medical Journal.
[70] O. Wolkowitz,et al. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women , 1999, Biological Psychiatry.
[71] A. Hofman,et al. Mutation screening of the tau gene in patients with early-onset Alzheimer's disease , 1999, Neuroscience Letters.
[72] P. Lee,et al. Smoking and Alzheimer's disease: a review of the epidemiological evidence. , 1994, Neuroepidemiology.
[73] R. Mayeux,et al. The influence of smoking on the risk of Alzheimer’s disease , 1999, Neurology.
[74] K. Yaffe,et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.
[75] V. Hachinski,et al. Prevalence and outcomes of vascular cognitive impairment , 2000, Neurology.
[76] M. Franceschi,et al. Headache in a Population‐Based Elderly Cohort. An Ancillary Study to the Italian Longitudinal Study of Aging (ILSA) , 1997, Headache.
[77] B. Winblad,et al. Smoking and the Occurence of Alzheimer's Disease: Cross-Sectional and Longitudinal Data in a Population-based Study , 1999 .
[78] A D Roses,et al. APOE is a major susceptibility gene for Alzheimer's disease. , 1994, Current opinion in biotechnology.
[79] Anthony Gamst,et al. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .
[80] Molecular genetics of Alzheimer’s disease , 2000, Biological Psychiatry.
[81] B L Miller,et al. Estrogen for Alzheimer’s disease in women , 2000, Neurology.
[82] W. Tsai,et al. Effect of Age, Ethnicity, and Head Injury on the Association between APOE Genotypes and Alzheimer's Disease , 1996, Annals of the New York Academy of Sciences.
[83] G. Belle,et al. Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.
[84] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[85] A. Roses. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease , 1994, Neurobiology of Aging.
[86] P. Gorelick,et al. Vascular Dementia: A Contemporary Review of Epidemiology, Diagnosis, Prevention, and Treatment , 1998, Journal of the American Geriatrics Society.
[87] Y. Stern,et al. Diabetes mellitus and the risk of dementia , 1999, Neurology.
[88] M. Pericak-Vance,et al. Apolipoprotein E ∈4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases , 1993, The Lancet.
[89] V. Henderson. Estrogen, cognition, and a woman's risk of Alzheimer's disease. , 1997, The American journal of medicine.
[90] J. Haines,et al. No association between the HLA-A2 allele and Alzheimer disease , 1999, Neurogenetics.
[91] V. Henderson. The epidemiology of estrogen replacement therapy and Alzheimer's disease , 1997, Neurology.
[92] L. Amaducci,et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging , 1998, Neurology.
[93] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[94] H. Braak,et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[95] Bette Phimister. Four companies announce discovery of β-secretase gene , 2000, Nature Biotechnology.
[96] J. Stewart,et al. Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia , 1999, Journal of neurology, neurosurgery, and psychiatry.
[97] H C Hendrie,et al. Epidemiology of dementia and Alzheimer's disease. , 1998, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[98] A. Hofman,et al. Incidence and risk of dementia. The Rotterdam Study. , 1998, American journal of epidemiology.
[99] C. Hock,et al. Risk factors and differential diagnosis of Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[100] R. Tanzi,et al. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. , 1999, The Journal of clinical investigation.